Pfizer said Tuesday it expects to apply for an emergency use permit for its COVID-19 vaccine in children aged 2 to 11 in September.
The company commented on the revenue call on Tuesday and also said it plans to apply for full approval from the Food and Drug Administration for the use of its vaccine between the ages of 16 and 85, outside the emergency use permit issued in December. Approval would be a milestone that could help alleviate some Americans’ worries and vaccine hesitation.
Pfizer added that a separate study on the effects of the vaccine in pregnant women would be launched in late July or early August.
The New York Times added that if the vaccine received full FDA approval, the drugmaker would be able to release it directly to consumers, although such a process could take months.
Last year, Pfizer said it would benefit from its vaccine, which is extremely effective in preventing COVID-19 infections. The strikes brought in $ 3.5 billion in the first three months of this year, about a quarter of the company’s total revenue.
The Times was the first to report on Monday that the FDA should extend the authorization for the Pfizer-BioNTech vaccine next week so that it can be used in children aged 12 to 15. The move will dramatically expand access to the inoculations of millions of young Americans and be a key step in the country’s battle against the pandemic.
The vaccine is currently approved for use in those over 16 years of age.
Vaccination of the general population will increase the level of immunity in the United States and reduce the number of hospitalizations and deaths. The new access to vaccines for children will also allow schools to reopen with some normalcy in the autumn.
More than 147 million people have received at least one dose of COVID-19 vaccine in the United States, including about 106 million who are now fully vaccinated. Despite these figures, the inoculation rate is declining, as vaccine volatility remains a key issue for millions of Americans.
HuffPost Guide to Coronavirus
Call all HuffPost super fans!
Sign up for membership to become a founding member and help shape the next HuffPost chapter